Anti-SARS-CoV-2 antibody kinetics up to 6 months of follow-up : Result from a nation-wide population-based, age stratified sero-epidemiological prospective cohort study in India
Copyright: © 2023 Misra et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited..
Repeated serological testing tells about the change in the overall infection in a community. This study aimed to evaluate changes in antibody prevalence and kinetics in a closed cohort over six months in different sub-populations in India. The study included 10,000 participants from rural and urban areas in five states and measured SARS-CoV-2 antibodies in serum in three follow-up rounds. The overall seroprevalence increased from 73.9% in round one to 90.7% in round two and 92.9% in round three. Among seropositive rural participants in round one, 98.2% remained positive in round two, and this percentage remained stable in urban and tribal areas in round three. The results showed high antibody prevalence that increased over time and was not different based on area, age group, or sex. Vaccinated individuals had higher antibody prevalence, and nearly all participants had antibody positivity for up to six months.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
PloS one - 18(2023), 12 vom: 11., Seite e0287807 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Misra, Puneet [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 10.02.2024 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1371/journal.pone.0287807 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365701599 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365701599 | ||
| 003 | DE-627 | ||
| 005 | 20240210232951.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1371/journal.pone.0287807 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1287.xml |
| 035 | |a (DE-627)NLM365701599 | ||
| 035 | |a (NLM)38079384 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Misra, Puneet |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-SARS-CoV-2 antibody kinetics up to 6 months of follow-up |b Result from a nation-wide population-based, age stratified sero-epidemiological prospective cohort study in India |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright: © 2023 Misra et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | ||
| 520 | |a Repeated serological testing tells about the change in the overall infection in a community. This study aimed to evaluate changes in antibody prevalence and kinetics in a closed cohort over six months in different sub-populations in India. The study included 10,000 participants from rural and urban areas in five states and measured SARS-CoV-2 antibodies in serum in three follow-up rounds. The overall seroprevalence increased from 73.9% in round one to 90.7% in round two and 92.9% in round three. Among seropositive rural participants in round one, 98.2% remained positive in round two, and this percentage remained stable in urban and tribal areas in round three. The results showed high antibody prevalence that increased over time and was not different based on area, age group, or sex. Vaccinated individuals had higher antibody prevalence, and nearly all participants had antibody positivity for up to six months | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Singh, Arvind Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Mishra, Baijayantimala |e verfasserin |4 aut | |
| 700 | 1 | |a Behera, Bijayini |e verfasserin |4 aut | |
| 700 | 1 | |a Patro, Binod Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Medigeshi, Guruprasad R |e verfasserin |4 aut | |
| 700 | 1 | |a Joshi, Hari Shanker |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmad, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Chaturvedi, Pradeep Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Chinnakali, Palanivel |e verfasserin |4 aut | |
| 700 | 1 | |a Haldar, Partha |e verfasserin |4 aut | |
| 700 | 1 | |a Bairwa, Mohan |e verfasserin |4 aut | |
| 700 | 1 | |a Kharya, Pradeep |e verfasserin |4 aut | |
| 700 | 1 | |a Dhodapkar, Rahul |e verfasserin |4 aut | |
| 700 | 1 | |a Rath, Ramashankar |e verfasserin |4 aut | |
| 700 | 1 | |a Guleria, Randeep |e verfasserin |4 aut | |
| 700 | 1 | |a Rai, Sanjay Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Kar, Sitanshu Sekhar |e verfasserin |4 aut | |
| 700 | 1 | |a Kant, Shashi |e verfasserin |4 aut | |
| 700 | 1 | |a Sarkar, Sonali |e verfasserin |4 aut | |
| 700 | 1 | |a Baidya, Subrata |e verfasserin |4 aut | |
| 700 | 1 | |a Meena, Suneeta |e verfasserin |4 aut | |
| 700 | 1 | |a Mandal, Suprakash |e verfasserin |4 aut | |
| 700 | 1 | |a Kishore, Surekha |e verfasserin |4 aut | |
| 700 | 1 | |a Majumder, Tapan |e verfasserin |4 aut | |
| 700 | 1 | |a Hada, Vivek |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PloS one |d 2006 |g 18(2023), 12 vom: 11., Seite e0287807 |w (DE-627)NLM167327399 |x 1932-6203 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g number:12 |g day:11 |g pages:e0287807 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1371/journal.pone.0287807 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |e 12 |b 11 |h e0287807 | ||